Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 13Fallopian Tube Neoplasms 4Recurrence 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Sarcoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma 2Breast Neoplasms 2Advanced Endometrial Cancer 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Endometrial Stromal 1Platinum-resistant Recurrent Ovarian Cancer 1Pelvic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasm Metastasis 1

Interventions

Doxorubicin 5Ifosfamide 4Filgrastim 3belinostat 2Radiotherapy 2Nivolumab 2Ipilimumab 2Imatinib Mesylate 2spartalizumab 1perifosine 1brostallicin 1balstilimab 1Vincristine 1Trabectedin 1Temozolomide 1Sunitinib 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1Fluorouracil 1Etoposide 1Epirubicin 1Dactinomycin 1Cyproheptadine 1Cyclophosphamide 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × Injections × Gynecologic × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡